Malignant fibrous histiocytoma

Common Name(s)

Malignant fibrous histiocytoma

Malignant fibrous histiocytoma is a rare form of cancer characterized by abnormal cell growth in the fibrous support tissue or the bone. Individuals with this disorder may grow harmful tumors in the muscles and bone that can spread to the rest of the body if not diagnosed and treated early. The abnormal cell growth usually develops in the extremities (toes, fingers etc.), but can also form anywhere in the body. This form of cancer can thus cause individuals to be less capable of performing important movements, like walking and running. Some individuals may loss their ability to move certain parts of their body (paralysis). Common symptoms include weight loss, abdominal pain and breathing problems. Diagnosis may require blood tests and imaging studies such as a CT scan. A physician may also need to take a biopsy, which is where they surgically remove a small portion of the tumor to look at under a microscope. Treatment is developed on a case-by-case basis and may include a combination of chemotherapy, radiation, and surgery.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Malignant fibrous histiocytoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Malignant fibrous histiocytoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Malignant fibrous histiocytoma" returned 165 free, full-text research articles on human participants. First 3 results:

Inflammatory malignant fibrous histiocytoma of the lung combined with fungal infection.
 

Author(s): Ji-Qiang Li, Ji-Ren Zhang, Long Li, Zhao-Jing Jiang, Xufeng Li, Rong Zeng, Yan-Fang Zheng

Journal: Chin. Med. J.. 2013 Nov;126(22):4379.

 

Last Updated: 18 Nov 2013

Go To URL
Primary malignant fibrous histiocytoma involving the left pulmonary vein presenting as a left atrial tumor.
 

Author(s): Saikat Bandyopadhyay, Sunip Banerjee, Abhijit Paul, Ratan Kumar Das

Journal: Ann Card Anaesth. ;16(4):293-5.

 

A 35-year-old woman presented with 4 months history of progressively increasing intermittent dyspnea and hemoptysis. Transthoracic echocardiography revealed a loculated mass in the left atrium (LA). A provisional diagnosis of LA myxoma was made. Intraoperatively the tumor was found ...

Last Updated: 10 Oct 2013

Go To URL
'Decoy' and 'non-decoy' functions of DcR3 promote malignant potential in human malignant fibrous histiocytoma cells.
 

Author(s): Mitsunori Toda, Teruya Kawamoto, Takeshi Ueha, Kenta Kishimoto, Hitomi Hara, Naomasa Fukase, Yasuo Onishi, Risa Harada, Masaya Minoda, Masahiro Kurosaka, Toshihiro Akisue

Journal: Int. J. Oncol.. 2013 Sep;43(3):703-12.

 

Decoy receptor 3 (DcR3) is a soluble secreted protein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. DcR3 inhibits the Fas ligand (FasL)/Fas apoptotic pathway by binding to FasL, competitively with Fas receptor. Previous studies have reported that overexpression ...

Last Updated: 18 Jul 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Malignant fibrous histiocytoma" returned 19 free, full-text review articles on human participants. First 3 results:

Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma.
 

Author(s): Si-Qi Qiu, Xiao-Long Wei, Wen-He Huang, Ming-Yao Wu, Yun-Sheng Qin, Yang-Kang Li, Guo-Jun Zhang

Journal: Sci Rep. 2013 ;3():2529.

 

We analyzed the clinicopathological features of 9 breast malignant fibrous histiocytoma (MFH) patients. Immunohistochemistry was used to make both diagnosis and differential diagnosis, and to identify prognostic factors. All tumors lacked epithelial markers but expressed mesenchymal ...

Last Updated: 28 Aug 2013

Go To URL
Malignant fibrous histiocytoma of right atrium.
 

Author(s): Huai-Sheng Chen, Wei Wang, Cheng-Ying Hong

Journal: Chin. Med. J.. 2013 ;126(10):1994-5.

 

Last Updated: 15 May 2013

Go To URL
A new complication of retained surgical gauze: development of malignant fibrous histiocytoma--report of a case with a literature review.
 

Author(s): Mehmet Kaplan, Halil Ibrahim Iyiköşker

Journal:

 

Primary visceral malignant fibrous histiocytoma (MFH) is a rare disease, and few cases have been reported in the English literature. However, retained foreign bodies in the abdomen after surgical procedures are important causes of intra-abdominal infections. For legal and ethical ...

Last Updated: 6 Aug 2012

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
 

Status: Recruiting

Condition Summary: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Fibrous Histiocytoma; Adult Malignant Mesenchymoma; Adult Neurofibrosarcoma; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Dermatofibrosarcoma Protuberans; Gastrointestinal Stromal Tumor; Metastatic Adult Malignant Fibrous Histiocytoma of Bone; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Metastatic Osteosarcoma; Ovarian Sarcoma; Recurrent Adult Malignant Fibrous Histiocytoma of Bone; Recurrent Adult Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Kaposi Sarcoma; Recurrent Osteosarcoma; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Uterine Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IV Uterine Sarcoma

 

Last Updated: 28 Jul 2014

Go to URL
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
 

Status: Recruiting

Condition Summary: Childhood Malignant Fibrous Histiocytoma of Bone; Sarcoma

 

Last Updated: 9 Aug 2013

Go to URL
Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
 

Status: Recruiting

Condition Summary: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Fibrous Histiocytoma; Adult Malignant Hemangiopericytoma; Adult Malignant Mesenchymoma; Adult Neurofibrosarcoma; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Childhood Alveolar Soft-part Sarcoma; Childhood Angiosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Childhood Epithelioid Hemangioendothelioma; Childhood Epithelioid Sarcoma; Childhood Fibrosarcoma; Childhood Leiomyosarcoma; Childhood Liposarcoma; Childhood Malignant Hemangiopericytoma; Childhood Malignant Mesenchymoma; Childhood Neurofibrosarcoma; Childhood Synovial Sarcoma; Dermatofibrosarcoma Protuberans; Metastatic Childhood Soft Tissue Sarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma

 

Last Updated: 26 Jul 2014

Go to URL